News

Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain
Jyong Biotech targets urinary disorders with a novel botanical pipeline, but clinical and liquidity risks temper near-term ...
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...
Targeted Oncology19h
Drug Approval Hurdles: Funding & Regulation Slow Life-Saving Cures
Unpredictable FDA and funding woes delay crucial drug approvals, depriving thousands of patients access to vital treatments ...
JD Supra22h
Before it hits the shelf: FDA reprocesses the new dietary ingredient notification process
On June 11, 2025, the US Food and Drug Administration (FDA) released educational materials to broaden dietary supplement manufacturers’ ...
Hims & Hers drops as U.S. lawmakers target copycat weight loss drugs
Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...
How to find out if weight loss drugs are covered by your insurance, and what to do if they're not
GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...
US FDA says J&J's unit issues correction related to surgical stapler
The U.S. drug regulator said on Friday a unit of Johnson & Johnson issued a correction for certain lots of a part related to ...
Applied Clinical Trials Online23h
FDA Crackdown on Trial Design: What July’s CRLs to Replimune and Capricor Mean for Sponsors
Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.